European Medicines Agency advises on compassionate use of daclatasvir/sofosbuvir combo
Cinnamon Girl said
Nov 27, 2013
Hi John, well early access though compassionate-use programmes will only apply to European member states, and at this stage it`s only a recommendation. It will be interesting to see what happens after daclatasvir has been given FDA approval, which should be some time next year. Let`s hope that many more people will be able to benefit from this very effective drug combo at some point in the future..
newmex said
Nov 26, 2013
Hmmm, wonder if this will have any effects in United States?
suziq said
Nov 26, 2013
Thanks Jill,
It is great to know that the Gilead/BristolMeyers combo that was so successful before the breakup of the companies will be available for those in dire need of treatment.
SuziQ
Matt Chris said
Nov 26, 2013
Hey Jill
Thanks for the info. it's good to see that this combo won't be ignored.
It shows that compassion can over rule greed for the good of mankind.
Also it will give needed hope for many people that really need hope.
matt
Cinnamon Girl said
Nov 26, 2013
22 Nov. 2013 - The European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) has given an opinion on the use of daclatasvir in combination with sofosbuvir in the treatment of chronic (long-term) hepatitis C virus (HCV) infection, in a compassionate-use programme.
The recommended compassionate use is intended for adult patients at a high risk of their liver being no longer able to function normally (decompensation) or death within 12 months if left untreated, and who have a genotype 1 infection. Further, it is recognised that the potential benefit of such combination therapy may extend to patients infected with other HCV genotypes.
Hi John, well early access though compassionate-use programmes will only apply to European member states, and at this stage it`s only a recommendation. It will be interesting to see what happens after daclatasvir has been given FDA approval, which should be some time next year. Let`s hope that many more people will be able to benefit from this very effective drug combo at some point in the future..
Hmmm, wonder if this will have any effects in United States?
Thanks Jill,
It is great to know that the Gilead/BristolMeyers combo that was so successful before the breakup of the companies will be available for those in dire need of treatment.
SuziQ
Hey Jill
Thanks for the info. it's good to see that this combo won't be ignored.
It shows that compassion can over rule greed for the good of mankind.
Also it will give needed hope for many people that really need hope.
matt
22 Nov. 2013 - The European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) has given an opinion on the use of daclatasvir in combination with sofosbuvir in the treatment of chronic (long-term) hepatitis C virus (HCV) infection, in a compassionate-use programme.
The recommended compassionate use is intended for adult patients at a high risk of their liver being no longer able to function normally (decompensation) or death within 12 months if left untreated, and who have a genotype 1 infection. Further, it is recognised that the potential benefit of such combination therapy may extend to patients infected with other HCV genotypes.
Full press release...
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001971.jsp